Aptevo Therapeutics Inc. Common Stock (APVO)
Stock · NASDAQ · Health Care
$1.69as of 10/16/2026
Price chart
Active signals
APVO Signal Track Record
How signals performed across all stocks →What APVO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 33 | -11.7% | 24% | August 12, 2026 |
| Volume Spike | 13 | -19.9% | 15% | September 17, 2026 |
| Bollinger Band Breakout | 10 | -24.4% | 20% | April 14, 2026 |
| Any 20-session window (baseline) | -15.3% | 19% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 33
- Website
- aptevotherapeutics.com/
Fundamentals
- 1-day range
- $1.6$1.73
- Market cap
- $6.18M
- P/E (trailing)
- 0.00
- P/E (forward)
- -0.16
- EPS (trailing)
- $-51.32
- Dividend yield
- —
- Beta
- 1.68
- Avg. volume
- 94.5K
- Dividend pay date
- March 27, 2020
How Aptevo Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 30, 2023 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Aptevo Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- APVOAptevo Therapeutics Inc. Common Stock$1.62▼ 4.71%Market cap $6.18MP/E 0.00$1.37$30.06
- HCWBHCW Biologics Inc. Common Stock$1.24▲ 0.81%Market cap $6.19MP/E —$1.14$27.3
- GELSGelteq Limited Ordinary Shares$0.446▲ 3.48%Market cap $6.15MP/E —$0.387$2.01
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.1▼ 5.98%Market cap $6.27MP/E —$1.15$7.87
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
- PULMPulmatrix Inc. Common Stock$1.36▼ 3.55%Market cap $6.06MP/E —$1.16$5.24
- SILOSilo Pharma Inc. Common Stock$1.18▼ 1.67%Market cap $5.85MP/E —$1.3$10.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| APVO Aptevo Therapeutics Inc. Common Stock | $6.18M | 0.00 | $1.62 | ▼ 4.71% | $1.37$30.06 |
| HCWB HCW Biologics Inc. Common Stock | $6.19M | — | $1.24 | ▲ 0.81% | $1.14$27.3 |
| GELS Gelteq Limited Ordinary Shares | $6.15M | — | $0.446 | ▲ 3.48% | $0.387$2.01 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.1 | ▼ 5.98% | $1.15$7.87 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
| PULM Pulmatrix Inc. Common Stock | $6.06M | — | $1.36 | ▼ 3.55% | $1.16$5.24 |
| SILO Silo Pharma Inc. Common Stock | $5.85M | — | $1.18 | ▼ 1.67% | $1.3$10.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Jeffrey G. Lamothe · August 6, 2026 · Option Exercise961
- SoYoung Kwon · August 6, 2026 · Option Exercise638
- Dirk Huebner · August 6, 2026 · Option Exercise638
- Dirk Huebner · August 6, 2026 · Tax Withholding156 @ $4.07
- Grady Grant III · August 6, 2026 · Option Exercise400
- Barbara Lopez Kunz · August 6, 2026 · Option Exercise400
- John Niederhuber · August 6, 2026 · Option Exercise400
- Marvin L. White · August 6, 2026 · Option Exercise1.7K
- Marvin L. White · August 6, 2026 · Tax Withholding406 @ $4.07
- Daphne Taylor · August 6, 2026 · Option Exercise638
- Daniel Abdun-Nabi · August 6, 2026 · Option Exercise400
- Zsolt Harsanyi · August 6, 2026 · Option Exercise400
- Marvin L. White · July 17, 2026 · Option Exercise1
Institutional Ownership
March 31, 2026
- Total shares held
- 49.6K
- Total value held
- $128.1K
- Institutional holders
- 8
- Unknown19.6K
- Unknown13.3K
- Unknown12.7K
- Unknown3.4K
- Unknown360
- Unknown109
- Unknown5
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
APVO to Present Multispecific Platform at SITC 2026 Meeting
Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.
APVO to Present Multispecific Platform at SITC 2026 Meeting. Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.